You are a helpful, respectful, and honest assistant. Always answer as helpfully as possible, while being safe. Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content. Please ensure that your responses are socially unbiased and positive in nature. If a question does not make any sense or is not factually coherent, explain why instead of answering something not correct. If you don't know the answer to a question, please don't share false information.
What is Recently approved NMDA blocker for the management of treatment resistant depression in adults is? and explain in detail?
ESKETAMINE: a. Non - Competitive NMDA receptor antagonist b. Used for treatment of Resistant Depression in Adults c. Supplied as a spray for intranasal administration d. Comes with a BLACK BOX WARNING: 1. Risk for sedation and dissociation after administration 2. Potential for abuse and misuse 3. Increased risk of suicidal thoughts and behaviors in pediatrics and young adult patients taking antidepressants SIPONIMOD: a. Used for treatment for relapsing form of Multiple Sclerosis (MS). b. Oral administration c. Sphingosine -1- phosphate (S1P) receptor Modulator like FINGOLIMOD d. SIPONIMOD blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in Peripheral blood. ERDAFITINIB: a. Tyrosine kinase inhibitor b. Used for bladder cancer RISANKIZUMAB: a. Mab against IL-23 b. Used in Plaque Psoriasis